In short
Clinical trials are studying IBUZATRELVIR in people with COVID-19, including adults and adolescents who are not hospitalized but are at risk for severe disease, and adults with a severely weakened immune system. These studies are checking whether IBUZATRELVIR can improve outcomes such as hospital visits, hospitalization, death, and signs of ongoing infection.
Key points
- Clinical trials of IBUZATRELVIR are studying COVID-19 in two main groups: people who are not hospitalized but are at risk for severe illness, and people with a severely weakened immune system. Both trials are Phase 3 studies, which means they are testing the medicine in larger groups and comparing results with placebo or other treatment options. The main goals are to see whether IBUZATRELVIR can lower emergency department visits, hospitalization, and death. One study also looks at whether it helps with ongoing or returning SARS-CoV-2 infection. The trials are authorised and together include adult and adolescent participants, with one study also testing IBUZATRELVIR together with remdesivir.
Trial overview
Two authorised Phase 3 clinical trials are studying IBUZATRELVIR in people with COVID-19. One trial is in nonhospitalized adults and adolescents who are at high risk for severe disease, and the other is in adults with a severely compromised immune system.
Who is being studied
The first study includes adult and adolescent patients with COVID-19 who are not in the hospital but may be more likely to become seriously ill. The second study includes symptomatic adults with COVID-19 who are severely immunocompromised, which means their immune system is very weak.
These groups are important because they may need extra protection against worsening illness or ongoing infection.
Trial design and phase
Both studies are interventional, which means researchers give study treatment and then measure the results. Both are in Phase 3, a later stage of research that usually tests a treatment in larger groups and compares it with placebo or another active treatment.
The first study plans to enroll 2,330 participants, while the second study plans to enroll 300 participants. Both studies are currently listed as authorised.
What the trials measure
The main result in the first study is the proportion of participants who have a COVID-19-related emergency department visit, receive supplemental oxygen, receive antiviral or intravenous treatment, are hospitalized, or die from any cause by Day 28. This is a composite endpoint, which means several important events are grouped into one main outcome.
The second study uses a similar main outcome by Day 38, including emergency department visits, hospitalization, or death, and it also looks for evidence of recurrent or persistent SARS-CoV-2 infection. This means the study is checking both clinical recovery and whether the virus is still present or comes back.
Study comparisons and treatment groups
The first trial compares IBUZATRELVIR with placebo, which is an inactive treatment used for comparison. The trial description says the study medicine is given as a film-coated tablet, and the comparison group receives placebo.
The second trial studies IBUZATRELVIR alone and also in combination with remdesivir, with matching placebo groups for comparison. The trial is designed to compare clinical and virological responses in severely immunocompromised adults with COVID-19.
Key points for patients
These trials are focused on people with COVID-19 who may have a greater risk of serious outcomes. The studies are not about routine care; they are research studies that aim to see whether IBUZATRELVIR can improve important health outcomes in specific patient groups.
Because the studies are Phase 3, they are looking at how well the treatment works in larger groups and how it compares with placebo or another treatment strategy. The results are meant to help show whether the study medicine can reduce worsening illness, hospital-level care, and ongoing infection.